Patents Assigned to Hanmi Pharmaceutical Co., Ltd.
-
Publication number: 20240067613Abstract: A novel quinazoline compound having SOS1 inhibitory activity and uses of the quinazoline compound are disclosed. More particularly, the present invention relates to a novel quinazoline derivative compound having inhibitory activity on SOS1 binding to RAS family proteins and/or RAC1, to pharmacologically acceptable salts thereof, and to pharmaceutical compositions containing the quinazoline compound. The novel quinazoline compound has the following chemical formula 1: wherein all the variables have meaning as defined in the specification.Type: ApplicationFiled: December 14, 2021Publication date: February 29, 2024Applicant: HANMI PHARMACEUTICAL CO., LTD.Inventors: Jae Yul CHOI, Won Jeoung KIM, Ji Sook KIM, Min Jeong KIM, Won Gi PARK, Young Gil AHN, In Hwan BAE
-
Patent number: 11883402Abstract: This patent document relates to the crystalline forms of a quinazoline compound and the hydrochloride salts thereof. More particularly, this patent document relates to a preparation method of the crystalline forms of 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one and its hydrochloride salts.Type: GrantFiled: September 12, 2019Date of Patent: January 30, 2024Assignees: Hanmi Pharmaceutical Co., Ltd., Spectrum Pharmaceuticals, Inc.Inventors: Jong Ouk Baek, Hee Cheol Kim, Tae Hee Ha, Kweehyun Suh, Guru Reddy
-
Patent number: 11827697Abstract: An anti-PD-1/anti-VEGF natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof. Provided are a highly stable, heterodimeric form anti-PD-1/anti-VEGF bispecific antibody having natural IgG characteristics and free of mismatched heavy and light chains and preparation method for the antibody. The bispecific antibody is capable of simultaneously binding with two target molecules and provides improved efficacy in treating a complicated disease.Type: GrantFiled: February 2, 2019Date of Patent: November 28, 2023Assignee: Beijing Hanmi Pharmaceutical Co., Ltd.Inventors: Yaping Yang, Nanmeng Song, Wenchu Xiao, Zhenlei Li, Lina Zhang, Mingyue Gu, Chunguang Zhan, Jiawang Liu, Maengsup Kim
-
Patent number: 11753471Abstract: Provided are an anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and a method of preparing the same. More particularly, provided are a highly stable heterodimeric anti-PD-1/anti-HER2 bispecific antibody having natural IgG characteristics without mismatch between a heavy chain and a light chain, and a method of preparing the same. The bispecific antibody may bind to two target molecules simultaneously and has excellent effects in treatment of a complex disease.Type: GrantFiled: February 8, 2019Date of Patent: September 12, 2023Assignees: BEIJING HANMI PHARMACEUTICAL CO., LTD., INNOVENT BIOLOGICS (SUZHOU) CO., LTD.Inventors: Jiawang Liu, Nanmeng Song, Yaping Yang, Maeng Sup Kim, Yao Yan, Qingqing Yin
-
Patent number: 11739151Abstract: Provided are an anti-PD-L1/anti-CD47 bispecific antibody that has natural IgG characteristics and is in a highly stable heterodimer form without the heavy chain and light chain being mismatched, and a preparation method therefor. Either the first Fc chain or second Fc chain of the bispecific antibody comprises amino acid substitutions at positions 366 and 399, and the other comprises amino acid substitutions at positions 351, 407 and 409.Type: GrantFiled: December 1, 2018Date of Patent: August 29, 2023Assignee: Beijing Hanmi Pharmaceutical Co., Ltd.Inventors: Jiawang Liu, Yaping Yang, Nanmeng Song, Maengsup Kim
-
Patent number: 11535629Abstract: Disclosed are novel dioxoisoquinolinone derivative compounds, pharmaceutically acceptable salts thereof, optical isomers, hydrates, and solvates thereof as well as uses thereof. More specifically, the novel dioxoisoquinolinone derivative compounds, pharmaceutically acceptable salts, optical isomers, hydrates, solvates show inhibition activity of EZH1 (Enhancer of zeste homolog 1) and/or EZH2 (Enhancer of zeste homolog 2) activity. Pharmaceutical compositions containing the compound is also disclosed.Type: GrantFiled: May 20, 2021Date of Patent: December 27, 2022Assignee: HANMI PHARMACEUTICAL CO., LTD.Inventors: Seung Hyun Jung, Dong Jin Hong, Ji Young Hwang, Seo Hee Kim, So Min Park, Shin Mee Mah, Young Gil Ahn
-
Patent number: 11498977Abstract: The present invention provides a method for production of stable and highly specific heterodimeric immunoglobulin constructs, e.g., bispecific antibodies, retaining desirable properties of native IgG and lacking undesirable heavy chain-light chain mispairing, that can simultaneously bind two target molecules and are more potent in the treatment of complex diseases.Type: GrantFiled: September 28, 2017Date of Patent: November 15, 2022Assignee: BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Jiawang Liu, Nanmeng Song, Dongge Yang, Yaping Yang, Maengsup Kim
-
Publication number: 20220275000Abstract: Disclosed are novel dioxoisoquinolinone derivative compounds, pharmaceutically acceptable salts thereof, optical isomers, hydrates, and solvates thereof as well as uses thereof. More specifically, the novel dioxoisoquinolinone derivative compounds, pharmaceutically acceptable salts, optical isomers, hydrates, solvates show inhibition activity of EZH1 (Enhancer of zeste homolog 1) and/or EZH2 (Enhancer of zeste homolog 2) activity. Pharmaceutical compositions containing the compound is also disclosed.Type: ApplicationFiled: May 20, 2021Publication date: September 1, 2022Applicant: HANMI PHARMACEUTICAL CO., LTD.Inventors: Seung Hyun JUNG, Dong Jin HONG, Ji Young HWANG, Seo Hee KIM, So Min PARK, Shin Mee MAH, Young Gil AHN
-
Publication number: 20220135582Abstract: A novel heterotricyclic compounds of Formula 1 or pharmaceutically acceptable salts thereof, and uses thereof are disclosed. The novel heterotricyclic compounds exhibit an inhibitory activity against EZH1 (enhancer of zeste homolog 1) and/or EZH2 (enhancer of zeste homolog 2) activity. Pharmaceutical compositions containing these compounds as active ingredient is also disclosed. The heterotricyclic compound, pharmaceutically acceptable salts thereof, or compositions containing the compound or salt are useful in treating tumor or cancer in a subject.Type: ApplicationFiled: February 19, 2020Publication date: May 5, 2022Applicant: HANMI PHARMACEUTICAL CO., LTD.Inventors: Dong Jin HONG, Seung Hyun JUNG, Chang Hee PARK, Seo Hee KIM, Ji Young HWANG, Young Gil AHN
-
Patent number: 11319378Abstract: Provided are an anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and a method of preparing the same. Specifically, provided are a highly stable anti-PD-1/anti-HER2 heterodimeric bispecific antibody having characteristics of a natural IgG and having no mismatched heavy chain and light chain, and a method of preparing the same. The bispecific antibody may bind to both of two kinds of target molecules, and thus may be more effective in treating complex diseases.Type: GrantFiled: November 16, 2017Date of Patent: May 3, 2022Assignee: BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Jiawang Liu, Nanmeng Song, Yaping Yang, Maengsup Kim
-
Publication number: 20220010006Abstract: Provided are an anti-TNF?/anti IL-17A natural antibody structure-like heterodimer form of a bispecific antibody and a preparation method therefor, wherein the antibody can bind two target molecules simultaneously, and can be used for treating complex diseases.Type: ApplicationFiled: November 5, 2019Publication date: January 13, 2022Applicant: BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Jiawang LIU, Yaping YANG, Nanmeng SONG, Wenchu XIAO, Chulwoong CHUNG, Maengsup KIM
-
Patent number: 10988482Abstract: The present invention relates to a compound inhibiting the activity of an IRAK4 kinase, a pharmaceutical composition thereof, a use thereof in preparing drugs, a method in which same is used for inhibiting the activity of the IRAK4 kinase and a method in which same is used for treating and/or preventing IRAK4 kinase mediated diseases or conditions in mammals (particularly humans). The compound has a structural formula I.Type: GrantFiled: August 13, 2015Date of Patent: April 27, 2021Assignee: BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Baoyu Xue, Runa Zheng, Mi Young Cha, Maengsup Kim
-
Patent number: 10954232Abstract: The present disclosure relates to a novel substituted pyrazole derivative having an effect of inhibiting serine/threonine kinase activity targeting receptor ALK5 of TGF-?, and a pharmaceutical composition including the compound of the present disclosure as an active ingredient may be useful in preventing and/or treating cancers, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, pulmonary diseases, cardiovascular diseases or metabolic diseases, or other diseases associated with a decrease in TGF family signaling activity.Type: GrantFiled: June 30, 2017Date of Patent: March 23, 2021Assignee: HANMI PHARMACEUTICAL CO., LTD.Inventors: Kyung Ik Lee, Young Hee Jung, Ji Young Song, Seung Ah Jun
-
Publication number: 20210032343Abstract: Provided are an anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and a method of preparing the same. More particularly, provided are a highly stable heterodimeric anti-PD-1/anti-HER2 bispecific antibody having natural IgG characteristics without mismatch between a heavy chain and a light chain, and a method of preparing the same. The bispecific antibody may bind to two target molecules simultaneously and has excellent effects in treatment of a complex disease.Type: ApplicationFiled: February 8, 2019Publication date: February 4, 2021Applicants: BEIJING HANMI PHARMACEUTICAL CO., LTD., INNOVENT BIOLOGICS (SUZHOU) CO., LTD.Inventors: Jiawang LIU, Nanmeng SONG, Yaping YANG, Maeng Sup KIM, Yao YAN, Qingqing YIN
-
Patent number: 10781217Abstract: The present invention relates to an imidazopyridazine compound having cell growth inhibitory activity, and a pharmaceutical composition for preventing or treating cancer or a tumor including the same. The imidazopyridazine compound of Chemical Formula 1 according to the present invention has excellent cell growth inhibitory activity, and thus can be favorably used as a preventive or therapeutic agent for cancer or a tumor.Type: GrantFiled: January 23, 2018Date of Patent: September 22, 2020Assignee: HANMI PHARMACEUTICAL CO., LTD.Inventors: Young Jin Ham, Seok Jong Kang
-
Patent number: 10696675Abstract: A novel imidazopyridine derivative compound and uses thereof are disclosed.Type: GrantFiled: June 28, 2017Date of Patent: June 30, 2020Assignee: HANMI PHARMACEUTICAL CO., LTD.Inventors: Moon Sub Lee, Eun Young Byun, Ji Sook Kim, Won Jeoung Kim, Nam Du Kim, Seung Hyun Jung, Young Gil Ahn
-
Publication number: 20200062775Abstract: The present invention relates to a compound inhibiting the activity of an IRAK4 kinase, a pharmaceutical composition thereof, a use thereof in preparing drugs, a method in which same is used for inhibiting the activity of the IRAK4 kinase and a method in which same is used for treating and/or preventing IRAK4 kinase mediated diseases or conditions in mammals (particularly humans). The compound has a structural formula I.Type: ApplicationFiled: August 13, 2015Publication date: February 27, 2020Applicant: BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Baoyu Xue, Runa Zheng, Mi Young Cha, Maengsup Kim
-
Patent number: 10562902Abstract: Disclosed are a compound related to inhibiting the activity of an IRAK4 kinase, a pharmaceutical composition thereof, a use thereof in preparing drugs, a method in which same is used for inhibiting the activity of the IRAK4 kinase and a method in which same is used for treating and/or preventing IRAK4 kinase mediated diseases or conditions in mammals (especially humans). The compound has a structural formula I.Type: GrantFiled: August 12, 2016Date of Patent: February 18, 2020Assignee: Beijing Hanmi Pharmaceutical Co., Ltd.Inventors: Jiangcheng Xu, Qinguan Cai, Mi Young Cha, Maengsup Kim
-
Publication number: 20190389872Abstract: The present invention relates to an imidazopyridazine compound having cell growth inhibitory activity, and a pharmaceutical composition for preventing or treating cancer or a tumor including the same. The imidazopyridazine compound of Chemical Formula 1 according to the present invention has excellent cell growth inhibitory activity, and thus can be favorably used as a preventive or therapeutic agent for cancer or a tumor.Type: ApplicationFiled: January 23, 2018Publication date: December 26, 2019Applicant: HANMI PHARMACEUTICAL CO., LTD.Inventors: Young Jin HAM, Seok Jong KANG
-
Publication number: 20190367633Abstract: Provided are an anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and a method of preparing the same. Specifically, provided are a highly stable anti-PD-1/anti-HER2 heterodimeric bispecific antibody having characteristics of a natural IgG and having no mismatched heavy chain and light chain, and a method of preparing the same. The bispecific antibody may bind to both of two kinds of target molecules, and thus may be more effective in treating complex diseases.Type: ApplicationFiled: November 16, 2017Publication date: December 5, 2019Applicant: BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Jiawang LIU, Nanmeng SONG, Yaping YANG, Maengsup KIM